Inhibitor Compounds
Featured Publication:
From “Undruggable” to Drugged: Daraxonrasib Approval Accelerates the KRAS Drug Discovery Era
August 2026 | Aurora Biolabs News
The KRAS drug-discovery field has reached another major milestone.
On August 26, 2026, the U.S. FDA approved RASONQUE™ (daraxonrasib) from Revolution Medicines for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The once-daily oral drug is an inhibitor of the RAS GTPase family and represents the first approved broad RAS-targeted therapy for metastatic pancreatic cancer.
For decades, RAS—and especially KRAS—was considered one of the most difficult oncology targets to drug. The approval of daraxonrasib provides compelling validation that direct targeting of RAS-driven cancers is becoming a clinical reality.
A New Opportunity for KRAS Research
Daraxonrasib belongs to an emerging class of RAS(ON) multi-selective inhibitors designed to target active RAS signaling rather than focusing exclusively on a single KRAS mutation. Revolution Medicines reports that the approval was supported by the Phase 3 RASolute 302 study in metastatic pancreatic adenocarcinoma.
As broad RAS inhibitors, mutant-selective inhibitors, molecular-glue approaches, and combination strategies continue to advance, researchers need reliable biochemical tools to understand how compounds alter:
KRAS activation → KRAS protein interactions → downstream signaling → inhibitor response
Aurora Biolabs Supports the Next Generation of KRAS Drug Discovery
Aurora Biolabs offers KRAS/cRAF/CYPA/Inhibitor Assay Kits, recombinant KRAS proteins, and customized screening services for studying RAS signaling and evaluating new inhibitors.
Our TR-FRET-based platform enables researchers to investigate key interactions including:
KRAS–cRAF binding
KRAS–CYPA interactions
KRAS–CYPA–inhibitor complex formation
KRAS inhibitor dose-response and IC50 determination
Nucleotide-dependent KRAS activity
Comparison of inhibitors across KRAS WT and oncogenic mutants
Aurora Biolabs currently supports KRAS WT and multiple important mutants, including G12C, G12D, G12V and G13D, as described in our KRAS/cRAF/CYPA assay platform.
Why CYPA Matters
Cyclophilin A (CYPA) is emerging as an important component of novel strategies for targeting mutant KRAS. Small molecules that promote or alter KRAS–CYPA interactions can provide a different approach to controlling oncogenic RAS signaling.
Aurora Biolabs' KRAS/CYPA platform is designed to help researchers characterize these interactions and screen compounds that modulate KRAS–CYPA or KRAS–CYPA–inhibitor complexes.
The KRAS Drug Discovery Era Is Accelerating
The approval of daraxonrasib demonstrates how rapidly the RAS field is evolving—from a historically “undruggable” target toward an expanding landscape of clinically actionable therapeutic strategies.
Aurora Biolabs is ready to support researchers developing the next generation of KRAS and RAS-targeted therapies.
Explore our KRAS research solutions:
KRAS Recombinant Proteins | KRAS-cRAF Binding Assays | KRAS-CYPA Assays | Nucleotide Exchange Assays | Custom Assay Development | Compound Screening Services
Contact Aurora Biolabs
858-215-4510 | 858-374-6010
www.aurorabiolabs.com
Aurora Biolabs products and services are for research use only and are not intended for diagnostic or therapeutic use in humans.
